Literature DB >> 12684424

Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases.

Goro Sashida1, Junko H Ohyashiki, Akihiro Nakajima, Masahiko Sumi, Ken Kawakubo, Tetsuzo Tauchi, Kazuma Ohyashiki.   

Abstract

Myelodysplastic syndrome (MDS), which is known to be a preleukemic state, is a heterogeneous entity characterized by ineffective hematopoiesis and dysplastic morphological features. Most MDS patients show erosive telomeric repeats (TTAGGG)(n), without up-regulation of telomerase activity, suggesting that telomere shortening may be linked to cellular senescence in MDS. We measured telomere length in samples from 13 MDS patients and 8 healthy volunteers, based on telomere signals of individual chromosomes, using digital images of metaphases after quantitative fluorescence in situ hybridization (Q-FISH) with peptide nucleic acid probes and compared the results with results obtained with the standard method of determining terminal restriction fragment (TRF) length. In healthy volunteers, we found a significant correlation between TRF length and telomere fluorescence signals detected by Q-FISH, and a relatively wide distribution of fluorescence telomere signals was demonstrated in every sample. In contrast, we found no linear correlation between TRF length and telomere fluorescence signals in MDS, and most MDS patients showed weak telomere fluorescence signals, corresponding to short telomeres, with a narrow range compared with normal subjects. TRF length represented telomere DNA in whole marrow cells, whereas telomere fluorescence signals by Q-FISH represented only marrow metaphases corresponding to MDS-derived cells. Metaphases from most MDS patients showed homogeneous telomere shortening, irrespective of the presence of cytogenetic abnormality. In contrast, marrow metaphases from normal individuals showed a relatively wide range of telomere signals in each metaphase, indicating that in MDS cells, telomere shortening mechanisms that normally exist might be dysregulated. Therefore, analysis of telomere distribution as well as average telomere length detected by Q-FISH might be useful to clarify the telomere dynamics of MDS cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12684424

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

1.  Telomere length in myelodysplastic syndromes.

Authors:  Dana E Rollison; P K Epling-Burnette; Jong Y Park; Ji-Hyun Lee; Hyun Park; Kristen Jonathan; Ashley L Cole; Jeffrey S Painter; Mayenha Guerrier; Johana Meléndez-Santiago; William Fulp; Rami Komrokji; Jeffrey Lancet; Alan F List
Journal:  Leuk Lymphoma       Date:  2011-06-03

2.  Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.

Authors:  Monica Cabrero; Yiting Yu; Amit Verma; Hui Yang; Simona Colla; Yu Jia; Hong Zheng; Zach Bohannan; Irene Ganan-Gomez; Andrew Futreal; Koichi Takahashi; Lynda Chin; Hagop Kantarjian; Andrea Pellagatti; Teresa Bowman; Jacqueline Boultwood; Guillermo Garcia-Manero; Yue Wei
Journal:  Br J Haematol       Date:  2015-06-24       Impact factor: 6.998

3.  Telomere length and anaemia in old age: results from the Newcastle 85-plus Study and the Leiden 85-plus Study.

Authors:  Wendy P J Den Elzen; Carmen Martin-Ruiz; Thomas von Zglinicki; Rudi G J Westendorp; Thomas B L Kirkwood; Jacobijn Gussekloo
Journal:  Age Ageing       Date:  2011-05-27       Impact factor: 10.668

Review 4.  Telomere dysfunction in ageing and age-related diseases.

Authors:  Francesca Rossiello; Diana Jurk; João F Passos; Fabrizio d'Adda di Fagagna
Journal:  Nat Cell Biol       Date:  2022-02-14       Impact factor: 28.213

5.  No telomere shortening in marrow stroma from patients with MDS.

Authors:  A Mario Marcondes; Steven Bair; Peter S Rabinovitch; Ted Gooley; H Joachim Deeg; Rosana Risques
Journal:  Ann Hematol       Date:  2008-12-03       Impact factor: 3.673

6.  Clinical significance of telomere length and associated proteins in oral cancer.

Authors:  Rachana N Sainger; Shaila D Telang; Shilin N Shukla; Prabhudas S Patel
Journal:  Biomark Insights       Date:  2007-02-14

Review 7.  Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions.

Authors:  Theresa Vasko; Andrea Kaifie; Matthias B Stope; Thomas Kraus; Patrick Ziegler
Journal:  Int J Mol Sci       Date:  2017-10-28       Impact factor: 5.923

8.  Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency.

Authors:  L Yang; A Mailloux; D E Rollison; J S Painter; J Maciejewski; R L Paquette; T P Loughran; K McGraw; H Makishima; R Radhakrishnan; S Wei; X Ren; R Komrokji; A F List; P K Epling-Burnette
Journal:  Leukemia       Date:  2012-10-17       Impact factor: 11.528

9.  Specific plasma autoantibody reactivity in myelodysplastic syndromes.

Authors:  George I Mias; Rui Chen; Yan Zhang; Kunju Sridhar; Donald Sharon; Li Xiao; Hogune Im; Michael P Snyder; Peter L Greenberg
Journal:  Sci Rep       Date:  2013-11-22       Impact factor: 4.379

10.  Abnormal mRNA Expression Levels of Telomere-Binding Proteins Represent Biomarkers in Myelodysplastic Syndromes: A Case-Control Study.

Authors:  Baoshan Liu; Rongdi Yan; Jie Zhang; Bin Wang; Hu Sun; Xing Cui
Journal:  Turk J Haematol       Date:  2017-04-13       Impact factor: 2.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.